中文摘要：

目的 分析长病史感音神经性聋的药物治疗价值及其疗效的稳定性。方法对0．25-17年病史的28例感音神经性聋患者，予以金纳多、地塞米松和甲钻胺类药物静脉用药2周；对0．5～19年病史的13例感音神经性聋患者予以银杏叶片、强的松和甲钴胺片口服治疗2周。分别于治疗前、治疗后3d，7d、10d、14d、30d、60d行纯音测听检查，分析各频率听阈的变化情况。结果静脉用药组：痊愈2例（7．14％），显效3例（10．71％），有效13例（46．43％），无效10例（35．71％），总有效率64．29％；轻度聋患者治疗均有效，中度聋患者总有效率为80％，重度聋者37．5％治疗有效：极重度聋者62．5％有效。口服用药组：痊愈0例，显效0例，有效4例（30．77％），无效9例（69．23％）；4例治疗有效患者包括中度聋患者2例（2／3，66．67％），重度聋患者2例（2／6，33．33％）。两组间药物总有效率差异具有统计学意义（x^2=4．01，P〈0．05）。两用药组的药物疗效稳定性均好，两组间差异无显著性意义（P=0．397）。结论感音神经性聋患者，即使病史较长，仍有药物治疗价值，轻度和中度聋患者治疗效果较好，极重聋亦可行药物治疗以提高助听质量，治疗首选静脉用药。

英文摘要：

Objective To report outcomes of medication treatment in patients with chronic sensorineural hearing loss （SNHL）. Methods Twenty-eight patients with SNHL of 3 months to 17 years were treated with IV Ginaton （ginkgo biloba extracts）, dexamethasone, and mecobalamin for 2 weeks, while 13 patients with SNHL of half to nineteen years received oral Ginkgo leaf, dehydrocortisone and mecobalamin for 2 weeks. Audiometry was performed before and after treatment on Days 3, 7, 10, 14, 30 and 60. Results In patients who received Ⅳ treatment, complete recovery was seen 2 cases （7.14%）, significant improvement in 3 cases （10.71%）, partial improvement in 13 cases （46.43%）, and no effect in 10 cases （35.71%）. Hearing improved in all patients with mild hearing loss in this group. The rate of improvement was 80% in patients with moderate hearing loss, 37.5% in those with severe hearing loss, and 62.5% in those with profound hearing loss. No complete recovery or significant hearing improvement was seen in patients receiving oral drugs. In this group, 4 （30.77%） showed partial improvement including 2 of the 3 patients with moderate hearing loss and 2 of the 6 with severe hearing loss, and 9 （69.23%） showed no effect. More improvement was seen in patients receiving IV treatment than those taking oral drugs （X2= 4.01, P 〈 0.05）. The maintenance of therapeutic effects was good in the two groups （P = 0.397）. Conclusions There was therapeutic value for SNHL patients with long history. The therapeutic results would be better in patients with mild and moderate hearing loss than those with severe and profound SNHL. For patients with profound hearing loss, it＇s suggested receiving drug treatment to improve the quality of hearing aid. The administration by intravenous injection should be the optimization.